News | News By Subject | News by Disease News By Date | Search News

Depression News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
SAGE Therapeutics (SAGE) Boss Gets Overenthusiastic About Drug, Walks Back Discussion of M&A Activity     2/17/2017
Why Alkermes (ALKS)’ Depression Drug Candidate Has a Real Shot at Approval Despite Two Poor Trials     11/3/2016
Alkermes (ALKS) Rockets as Depression Drug Aces Key Late-Stage Trial     10/24/2016
SAGE Therapeutics (SAGE) Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression     9/6/2016
Janssen R&D Release: Esketamine Receives Breakthrough Therapy Designation from FDA for Major Depressive Disorder with Imminent Risk for Suicide     8/16/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial     8/5/2016
SAGE Therapeutics (SAGE)' Stock Explodes as Drug Eliminates Postpartum Depression in Mid-Stage Study     7/14/2016
e-Therapeutics Sees Mixed Data in Major Depression Drug Trial     2/15/2016
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression     1/29/2016
Stock Craters as Alkermes (ALKS)' Depression Drug Fails in Two Late-Stage Trials     1/22/2016
Pfizer (PFE)'s Pristiq Fails to Beat Placebo in Phase III MDD Study     12/23/2015
Pfizer (PFE) Zoloft Co-Inventor Ken Koe Dies at 90 Years of Age     10/14/2015
Neurocrine Biosciences (NBIX)'s NBI-98854 Hits Primary Enpoint in Phase III Study     10/9/2015
Re-Analysis of GlaxoSmithKline (GSK)’s Seroxat/Paxil Antidepressant Data Shows Lack of Transparency     9/17/2015
Allergan (AGN) Coughs Up $560 Million Cash for Naurex     7/27/2015

News from Around the Web
Pfizer (PFE)'s 'Basic" Depression Questionnaire Raises Questions     5/22/2017
First Blood Test To Accurately Diagnose Depression And Schizophrenia Developed, Yale Study Reveals     3/21/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters     2/14/2017
Startup NeuroQore Uses Magnetic Pulses To Treat Depression. Does This Mean No More Drugs?     2/13/2017
Why Struggling Alkermes (ALKS) Could Make a Comeback in 2017     2/7/2017
This App Uses A Game To Fight Depression, University of Washington Study     1/11/2017
Zapping The Brain Really Does Seem To Improve Depression, Rio Grande Neurosciences Study     1/11/2017
Early-Life Language Stimulation, Skills May Prevent Childhood Depression, University of Missouri Study Reveals     9/8/2016
You Can Tell If You’re Depressed By Checking Instagram... Yes, Seriously, Harvard Study     8/22/2016
Prenatal BPA Exposure Linked To Anxiety And Depression In Boys, Columbia University Study     8/17/2016
Correcting Metabolic Deficiencies May Improve Depression Symptoms, University of Pittsburgh Study     8/15/2016
Music Electroacupuncture Outperforms Antidepressant Drug For Depression, Healthcare Medicine Institute Study     8/15/2016
Can This Ring Diagnose Your Depression? Helsinki Reveals     8/8/2016
This App Is Conquering Insomnia And Depression At The Same Time, Big Health Reveals     7/28/2016
The DNA That Makes You Happy Can Also Make You Sad, University of Oxford Study     7/19/2016

Press Releases
Sunovion Announces FDA Acceptance For Review Of Supplemental New Drug Application For Latuda (Lurasidone HCI) For The Treatment Of Bipolar Depression In Children And Adolescents     6/30/2017
Marinus Pharma (MRNS) Launches The Ganaxolone Clinical Program In Patients With Postpartum Depression     6/27/2017
H. Lundbeck A/S (LUN.CO) And Takeda (TKPYY) Receive Complete Response Letter From The FDA For Trintellix (Vortioxetine) Snda     6/23/2017
SAGE Therapeutics (SAGE) Announces The Lancet Publishes Positive Phase II Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression     6/13/2017
Suven Life Sciences Ltd Announces Initiation Of Phase I Clinical Trial And First Dosing Of SUVN-911, A Neuronal Acetylcholine Nicotinic Receptor (Nachrs) Antagonist For Major Depressive Disorder (MDD)     5/25/2017
Sunovion Announces Positive Results From Study Evaluating Latuda (Lurasidone HCL) In Children And Adolescents With Bipolar Depression At Annual American Psychiatric Association Meeting     5/22/2017
NeuralStem Reports Last Subject Out In Phase II Trial Of NSI-189 For Major Depressive Disorder     5/18/2017
SAGE Therapeutics (SAGE) Receives Fast Track Designation For SAGE-217 For The Treatment Of Major Depressive Disorder     5/18/2017
Intra-Cellular Therapies (ITCI) Presents Data Supporting The Potential For Potent And Rapid Antidepressant Activity With Lumateperone     5/8/2017
FDA Clears MagVenture's New Non-Pharma Depression Device     5/8/2017
Click Therapeutics Announces Multiple Publications Of Clinical Data Supporting Digital Therapeutics Programs For Smoking Cessation And Major Depressive Disorder     4/25/2017
Relmada Therapeutics Announces FDA Fast Track Designation For D-Methadone For Adjunctive Treatment Of Major Depressive Disorder     4/13/2017
Roadblocks To Treatment For People Suffering From Depression Continue To Be Lifted With Next Generation NeuroStar     4/13/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox     4/6/2017
First Blood Test To Accurately Diagnose Depression And Schizophrenia Developed, Yale Study Reveals     3/21/2017

//-->